mercredi 5 septembre 2018

Onco Actu du 5 septembre 2018

1. Biologie

New clues found to understanding relapse in breast cancer [WUSTL]

4.5 Dép., diag. & prono. - Colorectal

Half of over-60s ignore lifesaving bowel cancer screening [Cancer Research UK]

5.1 Traitements - Pré-clinique

Focused delivery for brain cancers [WUSTL]

Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other Cancers [NCI]

5.10 Traitements - Essais

Unreported clinical trial of the week: Rociletinib (CO-1686) for patients with EFRG-mutant non-small-cell lung cancer (NCT02186301 & NCT02322281) [BMJ]

5.12 Immunothérapies

Immunotherapy could offer hope for some men with aggressive prostate cancers [Institute of Cancer Research]

5.12.5 Immunothérapies - Pharma

Merck's Keytruda threatens Pfizer, Merck KGaA's Bavencio with Merkel cell 'priority' tag [FiercePharma]

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer [Merck]

5.12.8 Immunothérapies - Economie

Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs [FiercePharma]

NHS to fund 'game-changing' personalised cancer drug [The Telegraph]

Deal for NHS to offer exciting new child cancer therapy [BBC News]

5.3 Traitements - FDA, EMA, NICE...

Britain loses medicines contracts as EU body anticipates Brexit [The Guardian]

5.3.4 Traitements - AMM (FDA, EMA,...)

European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer [Puma]

6.1 Observation

Severe fatty liver disease boosts risk for liver cancer [Reuters]

6.3 Associations/Fondations

When a parent gets cancer, what about the kids? [The Guardian]

6.6 Publications

European science funders ban grantees from publishing in paywalled journals [Science]

Science Without Publication Paywalls: cOAlition S for the Realisation of Full and Immediate Open Access [PLoS Medicine]

Radical open-access plan could spell end to journal subscriptions [Nature]

cOAlition S - Making Open Access a reality by 2020 [Science Europe]

6.7.1 IA/bioinformatique

Clinical Implications and Challenges of Artificial Intelligence and Deep Learning [JAMA]

From hype to reality: data science enabling personalized medicine [BMC Medicine]

6.7.3 DMP

Richard Smith: Ten years of working towards patients controlling their own health records [BMJ]

Good Documentation [JAMA]

6.8 Communication

How Rachael Bland and You, Me & the Big C transformed the conversation around cancer [The Guardian]